Drugs / Nivolumab-relatlimab FDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05328908 | Apr 2022 → Jul 2025 | colorectal neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nivolumab-relatlimab FDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05328908 ↗ |